Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Share News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 185.00
Bid: 180.00
Ask: 190.00
Change: 0.00 (0.00%)
Spread: 10.00 (5.556%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 185.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Tungsten West 'largest Western tungsten producer'

Mon, 16th Jan 2023 16:26

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Aterian PLC - Morocco-focused metal exploration and development company - Identifies several new high-priority geophysical anomalies at its 100%-owned Agdz copper and silver project. Increases the target area due for further exploration. Chair Charles Bray says: "We are currently working towards building a conceptual geological model for the project, which has already demonstrated some excellent high-grade copper and silver values, up to 26.5% copper and 448 grams per tonne of silver. The presence of multiple historical copper workings at Agdz provides further encouragement, with the project located in an established copper and silver mining district in the eastern Anti-Atlas of Morocco and is an additional exciting exploration opportunity in our Moroccan portfolio."

----------

Quadrise Fuels International PLC - London-based energy solutions provider for a cleaner planet - Says bioMSAR fuel arrived at it client site in Morocco during December. The fuel is currently at Moroccan customs, awaiting final clearance. Expects the remaining logistical issues will be resolved this month so that the trial can then proceed as planned. Expects a successful trial to follow via discussions to conclude a commercial fuel supply agreement in the first half of 2023 as planned. Also announces commercial discussions for licence supply in Utah, US, progressing well, working towards execution of definitive agreements by the first quarter of 2023. Chief Executive Officer Jason Miles says: "Whilst we are frustrated with the delays that we have faced in progressing some of our projects, we remain confident that these will be overcome soon. The team has worked extremely diligently to seek to navigate these challenges such that the impact on the delivery of our projects should be minimal."

----------

Poolbeg Pharma PLC - London-based biopharmaceutical company focusing on infectious diseases - Files patent application to protect use of POLB 001 for new oncology indication. Says scientific finding indicate POLB 001 has the potential to dampen the pro-inflammatory cytokine release syndrome affecting patients receiving CAR T cell therapies. Submits a patent application for the use of POLB 001 to treat CRS in CAR T cell patients. Says it is progressing towards trial initiation in 2024. Scientific advisory board member Brendan Buckley says: "By reducing runaway inflammation associated with CRS, POLB 001 has the potential to significantly reduce the serious adverse effects that many CAR T cell patients suffer. With 18 to 19 million cases of cancer diagnosed globally each year, the use of cell therapies is predicted to expand significantly over the coming years with the CAR T cell market expected to grow to an estimated USD6 billion by 2031...we look forward to updating the market as to the progress of this exciting programme."

----------

Coro Energy PLC - Leeds, England-based energy company with a natural gas and clean energy portfolio - Says production from its Italian portfolio continued in line with expectations during the fourth quarter of 2022, following record quarterly revenues in the preceding quarter. Revenue is EUR1.5 million in the fourth quarter, down from EUR2.0 million in the third quarter, and marginally down from EUR1.6 million in the second quarter. Says 1.4 million standard cubic metres of natural gas were produced during the fourth quarter, up from 1.2 million in the third quarter, but down from 1.6 million in the second quarter. Full year 2022 natural gas production is 5.1 million standard cubic metres and revenue is EUR6.0 million. In the week ended January 8, Italian portfolio production averaged 21,091 standard cubic metres per day, up 50% from the 2022 annual average of 13,979 standard cubic metres per day.

----------

Upland Resources Ltd - Malaysia-focused upstream oil and gas company - Believes it is "unequally positioned" in Sarawak, Malaysia, providing the December workflow update on the SK334 joint technical study activity. Says time and resources spent in adding value to the Sarawak SK334 JTS workstream has the potential to generate "significant returns" to shareholders. Chair & Chief Executive Officer Bolhassan Di says: "Block SK334 in Sarawak offers transformational potential for a company our size, sedimentary basins in Sarawak are proven prolific hydrocarbons bearing basins. We are encouraged by the continuing recent discoveries in surrounding blocks...Separately, we also recognise the potential emerging from our UK North Sea P2478 Dunrobin prospect and are working closely with the joint venture partners to realise value there as technical studies complete."

----------

Bradda Head Lithium Ltd - North America-focused lithium development group - Says updated mineral resource estimate at its Basin East project in the US state of Arizona has increased by 17%, alongside a 22% increase in tonnes contained lithium carbonate equivalent, based on "only" 1,200 metres of drilling. Says the 2022 drilling programme has given the company "great confidence" in the estimate at Basin East. Chief Executive Officer Charles FitzRoy says: "2023 is going to be an exciting year of resource growth for Bradda Head. With more drilling already planned at Basin East Extension and Basin North, Bradda Head is excellently placed to take full advantage of the near-term resource growth potential at our sedimentary lithium assets in Arizona."

----------

Tungsten West PLC - Mining company focused on restarting production at the Hemerdon tungsten and tin mine in Devon, England - Says post-tax net present value is GBP297 million with an internal rate of return of 25%. Projects Hemerdon average annual production to be 2,900 tonnes of tungsten trioxide in concentrate and 310 tonnes of tin in concentrate. Says life of mine is 27 years with an an annual average steady-state mining rate of 3.5 megatonnes per annum. Says LOM post financing free cash flow is GBP550 million. Believes feasibility study shows company could be the largest Western tungsten producer. Says GBP12 million of capital expenditure already spent, with remaining capex being GBP31.1 million as of October 1. Executive Vice Chair Mark Thompson says: "The feasibility study provides solutions to the energy price challenges and will enable increased operating efficiencies at the project...Tungsten is on both the EU and US lists of critical metals and due to geopolitical tensions and security of supply issues the market remains strong. With Hemerdon in production, we will provide an alternative source of tungsten to Western consumers in markets which are otherwise dominated by China."

----------

ICG-Longbow Senior Secured UK Property Debt Investments Ltd - Guernsey-based investment company with a portfolio of UK real estate debt investments - Receives remaining GBP6.5 million balance of its LBS loan alongside GBP300,000 in interest and fees, following a refinancing of the underlying property. Says the repayment allows the company to continue its programme of capital distributions to shareholders.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based biopharmaceutical company focusing on difficult-to-treat cancers and inflammation via precision immunotherapy - Reports encouraging additional data for bexmarilimab for the treatment of hematological malignancies. Says it provoked objective responses in 3 out of 5 patients doesed in the first doublet cohort of the phase 1 and 2 Bexmab study. Says study showed rapid enrolment in doublet and triplet combinations. "The additional BEXMAB data indicates that bexmarilimab contributed to positive responses in the refractory setting where patients failed standard of care," says Chief Medical Officer Marie-Louise Fjallskog. "We are excited about the initial promising results and look forward to gathering additional clinical data for more robust read-outs."

----------

ACP Energy PLC - Lutterworth, England-based company looking for value-accretive opportunities in the oil and gas industry - Says shares are suspended as it signs a sale and purchase agreement for an equity interest being sold by Vinncler CA. Vinncler own the producing assets of a "highly prolific" basin in Latin America currently producing around 4,100 barrels per day, says ACP Energy. Says the proposed acquisition is in line with ACP Energy's stated strategy of identifying and acquiring hydrocarbon producing assets that are either in production or near to production. Says the proposed acquisition, if completed, will constitute a reverse takeover.

----------

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
26 Jun 2019 11:52

Faron Pharmaceuticals Says Traumakine Study Hindered By Steroid Use

(Alliance News) - Faron Pharmaceuticals Oy on Wednesday said interim results from its phase two Inforaaa study support continuation but the study is limited by a lack of patients not also taking a

Read more
14 Jun 2019 11:54

Faron Pharmaceuticals' Analysis Explains "Disappointing" Prior Trial

(Alliance News) - Faron Pharmaceuticals Oy on Friday said analysis of a more recent trial of Traumakine has explained why the drug did not perform as expected in a previous trial.Shares in

Read more
14 Jun 2019 10:37

Faron Pharmaceuticals reports 'significant' findings from YODA study

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced results from its pharmacokinetic/dynamic 'YODA' study examining the administration of concomitant steroids and Traumakine in healthy volunteers on Friday.

Read more
24 May 2019 13:34

Faron Pharma Finance Head Wichmann Steps Down, Hanninen Replaces

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Friday said it has made several managerial changes, which it believes will strengthen its operating performance.The clinical stage said

Read more
24 May 2019 11:50

Faron appoints new CFO after some internal shuffling

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals updated the market on its board and management team on Friday, announcing that Yrjö Wichmann was leaving his current role as its chief financial officer to take up the new position of vice-president, financing and investor relations.

Read more
14 May 2019 14:16

Faron Pharmaceuticals Raises EUR1.3 Million Via Share Subscription (ALLISS)

LONDON (Alliance News) - Biopharmaceutical company Faron Pharmaceuticals Ltd said Tuesday that it has raised EUR1.3 million via share subscription.The company has issued 1.8 million shares

Read more
7 May 2019 11:44

Faron Pharmaceuticals Narrows Loss On Reduced Clinical Trial Costs

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Tuesday reported a slightly narrowed annual loss as the drug developer's research & development costs fell.Faron is a clinical

Read more
2 May 2019 17:30

Faron Pharmaceuticals Knows Of No Reason For 43% Share Price Jump

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it is unable to explain the recent movement in its share price.Faron noted Thursday's 43% share price rise, and said

Read more
30 Apr 2019 16:02

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 1 May J SainsburyFull Year ResultsConnect GroupHalf Year GroupQ1 Stock

Read more
29 Apr 2019 15:46

Faron Gets Results Of Traumakine Study From Japanese Licensing Partner

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said its Japanese licensing partner Maruishi Pharmaceutical Co Ltd has provided clinical trial results on its phase three Traumakine for

Read more
11 Apr 2019 12:13

Faron Pharmaceuticals To Focus On Colorectal Cancer In Clevegen Trial

LONDON (Alliance News) - Faron Pharmaceuticals Oy is to target colorectal cancer in its upcoming test programme for Clevegen, it said Thursday.The testing of Clevegen on patients with will

Read more
11 Apr 2019 11:22

Faron Pharmaceuticals upbeat on latest info from MATINS trial

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Thursday that the cohort expansion part of its phase 1 and 2 'MATINS' clinical trial, investigating the safety and efficacy of its wholly-owned novel precision cancer immunotherapy 'Clevegen', would begin with patients suffering from late-stage colorectal cancer as soon as the optimal dosing was determined.

Read more
26 Mar 2019 15:52

UPDATE: Faron Pharmaceuticals Raises EUR3.1 Million In Fundraise (ALLISS)

LONDON (Alliance News) - Finland's Faron Pharmaceuticals Oy on Tuesday afternoon said it has raised EUR3.1 million pursuant to a placing announced earlier in the day.The company issued

Read more
26 Mar 2019 12:05

Faron Pharmaceuticals Optimistic For Traumakine As It Plans Fundraise (ALLISS)

LONDON (Alliance News) - Finland's Faron Pharmaceuticals Oy on Tuesday said it expects further disappointing results from Traumakine, as it plans a share placing.Faron is currently for

Read more
21 Feb 2019 12:17

Faron "Very Encouraged" By Early Clevegen Trials In Cancer Patients

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Thursday said early results from a trial of its Clevegen cancer drug are encouraging.Shares in Faron were up 10% at 64.00 pence on said

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.